Trial · NCT06866444
Duloxetine Metabolism and Fibromyalgia
NCT06866444, Recruiting, University of Utah
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Duloxetine Metabolism and Fibromyalgia. Trials, record NCT06866444. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06866444
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Duloxetine Metabolism and Fibromyalgia
- NCT number
- NCT06866444
- Status
- Recruiting
- Enrollment
- 100 participants, estimated
- Lead sponsor
- University of Utah
- Conditions
- Fibromyalgia, Duloxetine
- Interventions
- Observational
- First posted
- 2025-03-10
- Last updated
- 2026-09-25
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Duloxetine concentrations across metabolizer phenotypes, 3 groups | Obtained four hours after morning duloxetine dose. | Metabolizer phenotypes will be separated into 3 groups based on diplotypes. Ultrarapid metabolizer phenotypes will be measured by having an activity score of greater than 2.0. Normal/intermediate metabolizer phenotypes will be measured by having an activity score between 1.0 to 2.0. Slow metabolizer phenotypes will be measured by having an activity score between 0.75 to 0. |
| Primary | Measure inhibitors and inducers of CYP1A2 and CYP2D6 in blood sample | Obtained four hours after the morning duloxetine dose. | Inhibitors and inducers of CYP1A2 and CYP2D6 are defined by the Drug Interaction Flockhart Table. A strong inhibitor will be measured by ≥ 5-fold increase in plasma AUC or more than 80% decrease in clearance. A moderate inhibitor will be measured by 2 to 5-fold increase in the plasma AUC or 50-80% decrease in clearance. |
| Secondary | Symptoms of fibromyalgia | From start of study visit to end (approximately 2 hours). | Measured by the Revised Fibromyalgia Impact Questionaire (FIQR) and ACR 2016 criteria for fibromyalgia. The FIQR is scored on a scale of 0-100, with higher scores (100) indicating a greater impact of fibromyalgia (worst outcome) and lower scores (0) indicating a lesser impact of fibromyalgia (better outcome). |
| Secondary | Vital signs, heart rate | One time at the start of the study visit. | Heart rate (bpm) will be recorded. |
| Secondary | Vital signs, noninvasive blood pressure | One time at the start of the study visit. | Blood pressure (mmHg) readings will be recorded. |
| Secondary | Vital signs, oxygen hemoglobin saturation | One time at the start of the study visit. | Oxygen hemoglobin saturation (Sp02 using pulse oximeter) will be recorded. |
| Secondary | Vital signs, temperature | One time at the start of the study visit. | Temperature (Celcius) will be recorded. |
| Secondary | Vital signs, respiratory rate | One time at the start of the study visit. | Respiratory rate will be recorded (via observation for 1 minute). |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06866444
GET https://conductscience.org/api/trials/v1/NCT06866444/registered